scholarly journals A case of light-chain-type multiple myeloma in a hemodialysis patient that was diagnosed based on an elevated free light chain κ/λ ratio alone

2020 ◽  
Vol 53 (2) ◽  
pp. 93-98
Author(s):  
Fumiko Kojima ◽  
Yoshiko Tanaka ◽  
Midori Ishiyama ◽  
Junji Tanaka ◽  
Atsushi Suzuki ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Light Chain ◽  
Hemodialysis Patient ◽  
Free Light Chain ◽  
Light Chain Type ◽  
Chain Type

A Case of Eosinophilic Pleural Effusion Complicating Multiple Myeloma

1988 ◽  
Vol 33 (3) ◽  
pp. 278-278 ◽  
Author(s):  
B.J. Lipworth ◽  
D.P. Dhillon
Keyword(s):  
Multiple Myeloma ◽  
Pleural Effusion ◽  
Light Chain ◽  
Recent Literature ◽  
Rare Complication ◽  
Light Chain Type ◽  
First Case ◽  
Eosinophilic Pleural Effusion ◽  
Chain Type

Pleural effusion is a rare complication of multiple myeloma. We report the first case of eosinophilic effusion due to light chain type disease and review the recent literature.

scholarly journals Isotypic discordance of paraproteins and lymphocyte surface immunoglobulins in myeloma

Blood ◽  
1981 ◽  
Vol 57 (1) ◽  
pp. 192-195 ◽  
Author(s):  
M Nicholls ◽  
PC Vincent ◽  
E Repka ◽  
J Saunders ◽  
FW Gunz
Keyword(s):  
Multiple Myeloma ◽  
Heavy Chain ◽  
Light Chain ◽  
B Lymphocyte ◽  
Plasma Cells ◽  
Light Chains ◽  
Lymphocyte Surface ◽  
Light Chain Type ◽  
Surface Immunoglobulins ◽  
Chain Type

Abstract B lymphocyte surface immunoglobulins (Smlg) were studied in 24 patients with multiple myeloma by means of anti-isotypic antisera, and their heavy and light chain isotypes were compared in each patient with those of the paraprotein. In 21 patients, lymphocyte Smlg consisted of only one light chain type, and in 16 of only 1 heavy chain type. However, the Smlg and paraprotein heavy and light chain types were identical in only 5 patients while in 6 they differed in heavy and light chain types, in 7 in light chain type, and in 4 in heavy chain type. In 2 patients with light chain myeloma, Smlg light chains were isotypically the same as the paraprotein. Isotypic discordance between paraprotein and Smlg may signify the proliferation of a second malignant clone with failure to differentiate into secreting plasma cells. Alternatively, it is conceivable that the lymphocyte Smlg could have the same idiotypic specificity as the paraprotein despite the isotypic differences, but this will require further studies using anti-idiotypic antisera.

scholarly journals Isotypic discordance of paraproteins and lymphocyte surface immunoglobulins in myeloma

Blood ◽  
1981 ◽  
Vol 57 (1) ◽  
pp. 192-195
Author(s):  
M Nicholls ◽  
PC Vincent ◽  
E Repka ◽  
J Saunders ◽  
FW Gunz
Keyword(s):  
Multiple Myeloma ◽  
Heavy Chain ◽  
Light Chain ◽  
B Lymphocyte ◽  
Plasma Cells ◽  
Light Chains ◽  
Lymphocyte Surface ◽  
Light Chain Type ◽  
Surface Immunoglobulins ◽  
Chain Type

B lymphocyte surface immunoglobulins (Smlg) were studied in 24 patients with multiple myeloma by means of anti-isotypic antisera, and their heavy and light chain isotypes were compared in each patient with those of the paraprotein. In 21 patients, lymphocyte Smlg consisted of only one light chain type, and in 16 of only 1 heavy chain type. However, the Smlg and paraprotein heavy and light chain types were identical in only 5 patients while in 6 they differed in heavy and light chain types, in 7 in light chain type, and in 4 in heavy chain type. In 2 patients with light chain myeloma, Smlg light chains were isotypically the same as the paraprotein. Isotypic discordance between paraprotein and Smlg may signify the proliferation of a second malignant clone with failure to differentiate into secreting plasma cells. Alternatively, it is conceivable that the lymphocyte Smlg could have the same idiotypic specificity as the paraprotein despite the isotypic differences, but this will require further studies using anti-idiotypic antisera.

Clinical Experience and Prognostic Factors with Bortezomib-Combined Regimen in 40 Patients with Multiple Myeloma

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5211-5211
Author(s):  
Juan Li ◽  
Ying Zhao
Keyword(s):  
Multiple Myeloma ◽  
Renal Function ◽  
Prognostic Factors ◽  
Adverse Effects ◽  
Light Chain ◽  
Response Rate ◽  
Total Response ◽  
Light Chain Type ◽  
Total Response Rate ◽  
Chain Type

Abstract To explore the medical effects, prognostic factors relating to the effects and side effects of bortezomib-combined regimen in treatment of multiple myeloma (MM), and evaluate the safety of this regimen in patients with special conditions. Methods: Forty newly diagnosed and relapsed or refractory MM treated with the regimen of combination of bortezomib and dexamethasone in a cycle of 3 weeks. All of the patients received a median of 3 (1–9) cycles of the treatment. Response to bortezomib was evaluated according to the criteria of the European Group for Blood and Marrow Transplantation (EBMT) and adverse events were graded according to the National Cancer Institute Common Toxicity Criteria. Results: Total response rate was 75.0% (30/40), and the rate of CR+nCR was 42.5% (17/40). Eighty percent patients (24/30) showed effects after the first cycle, although the median time of best effect was 2 cycles. Compare to the other types, light-chain type had higher total response rate (100.0% vs. 65.5%, P=0.038)and CR rate (36.4% vs. 6.9%, P=0.039), and also responded earlier with 81.8% (9/11) patients reached the best effect after the first cycle. The factors which showed no relationship to the effects were age (<65 years vs. >65 years, P=0.081), sex (P=0.696), DS staging (P=1.0), ISS staging(P=0.969), newly or retreated (P=0.731), using thalidomide or not(P=0.338), renal function damage or not(P=0.401), PLT level(P=1.0), hypercalcemia or not(P=0.306), Hb level(P=0.70)and the ratio of tumor cells in bone marrow(P=0.693). Grade III~IV adverse effects in this VD regimen was low, including leucocytopenia, thrombocytopenia, diarrh ea and debility, could be relieved by symptomatic treatment or delay the chemotherapy. The rate of infection was high and which was one of the important cause of death. Renal function improvement could be showed in all of the 10 patients who had renal inadequacy, and compared with normal patients, the incidences of side and adverse effects had no statistical differences. Conclusion: The Bortezomib combination regimen has significant effect in MM treatment. It shows more significant in light-chain type patients, and show earlier effect onset. This regimen can be tolerant in most patients, and is also safe in patients with renal inadequacy.

scholarly journals Involved free light chain: an early independent predictor of response and progression in multiple myeloma

2021 ◽  
pp. 1-8
Author(s):  
Charlotte Gran ◽  
Gabriel Afram ◽  
Johan Liwing ◽  
Andre Verhoek ◽  
Hareth Nahi
Keyword(s):  
Multiple Myeloma ◽  
Light Chain ◽  
Independent Predictor ◽  
Free Light Chain

scholarly journals Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein

2018 ◽  
Vol 93 (10) ◽  
pp. 1207-1210 ◽  
Author(s):  
Marcella Tschautscher ◽  
Vincent Rajkumar ◽  
Angela Dispenzieri ◽  
Martha Lacy ◽  
Morie Gertz ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Light Chain ◽  
Free Light Chain ◽  
Serum Free ◽  
Monoclonal Protein ◽  
Serum Free Light Chain
Sign in / Sign up

Export Citation Format

Share Document